The Cancer Biology and Biotechnology Research Program at the University of New Mexico Cancer Center is a highly interactive transdisciplinary program with 24 Program Members from 6 Departments in the UNM School of Medicine (Biochemistry and Molecular Biology, Cell Biology and Physiology, Medicine, Molecular Genefics and Microbiology, Neurology, and Pathology), the UNM College of Pharmacy, 3 Departments on the UNM Main Campus (Biology, Chemical and Nuclear Engineering, and Physics and Astronomy), New Mexico State University (Chemistry), and Sandia and Los Alamos Nafional Laboratories. The Program has two scientific themes; the first: Chromosome Dynamics and Macromolecular Interactions has the goals of (1) discovering the fundamental mechanisms of tumorigenesis through studies of epigenefic, transcripfional, cell growth control, and DNA damage repair pathways in cancer cells and model organisms; and (2) exploiting studies of viral protein-nucleic acid interacfions for translafion into new dlagnosfic or therapeufic platforms. The second program theme: Biotechnology and Target Screening has the overall goal of discovering and validating novel targets and small molecules from these fundamental regulatory pathways for cancer diagnosis, screening, prevention, and therapy. To achieve the goals of this second theme, program members develop and utilize (1) high-throughput small molecule screening, high performance compufing, cheminformafics, and animal modeling; (2) novel isotopes and imaging; and (3) micro- and nanotechnology to discover, screen, and model new cancer targets. Since the prior NCI CCSG review in 2005, the Program's funding, intraprogrammafic, and inter-programmafic interacfions have all increased dramafically. Program members direct one of only 9 nafional, mulfi-invesfigator NIH Roadmap-funded Center Grants for target screening and chemical biology: The UNM Center for Molecular Discovery (U54MH084690) which is collaborating with each UNM Cancer Center Research Program and several other NCI Cancer Centers to screen and characterize over 30 novel cancer targets. Program members also recenfiy received nofice of the funding of two highly compefifive NCI ARRA Challenge Grants {RC2CA148982; RC1EB/CA010617). As of September 2009, Program Members at the UNM Cancer Center and its consortium institufions held $9,538,635 in total annual direct funding (represenfing an 80% increase in funding since 2005) of which $8,365,143 was peer-reviewed ($1,537,027 from NCI and $6,828,116 from NIH, NSF, DOD, and DOE). Program members at New Mexico State University held an additional $2,965,296 in annual peer-reviewed funding. In 2008, program members published a total of 53 cancer-relevant publicafions, of which 27% were intra-programmafic and 48% were inter-programmatic.

Public Health Relevance

Cancer is a multifactorial disease that requires transdisciplinary approaches to understand its etiology and translate these discoveries to more effective diagnostics and therapeutics. The goals of The Cancer Biology and Biotechnology Program are to study the most fundamental cellular pathways that are perturbed in human cancers and that promote cancer efiology and progression and to develop and use the most innovative science and technology to discover and characterize new cellular targets that can be used to diagnosis, screen, prevent, and treat human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA118100-08
Application #
8379119
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
8
Fiscal Year
2012
Total Cost
$30,465
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Kumar, Suresh; Jain, Ashish; Farzam, Farzin et al. (2018) Mechanism of Stx17 recruitment to autophagosomes via IRGM and mammalian Atg8 proteins. J Cell Biol 217:997-1013
Vicuña, Belinda; Delaney, Harold D; Flores, Kristina G et al. (2018) Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families. J Community Genet 9:81-92
Feng, Bing; Hoskins, William; Zhang, Yan et al. (2018) Bi-stream CNN Down Syndrome screening model based on genotyping array. BMC Med Genomics 11:105
Phinney, Brandon B; Ray, Anita L; Peretti, Amanda S et al. (2018) MK2 Regulates Macrophage Chemokine Activity and Recruitment to Promote Colon Tumor Growth. Front Immunol 9:1857
Kuehl, Philip J; Grimes, Marcie J; Dubose, Devon et al. (2018) Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Deliv 25:1127-1136
Köbel, Martin; Luo, Li; Grevers, Xin et al. (2018) Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. Int J Gynecol Pathol :
Bredemeyer, Andrea L; Edwards, Bruce S; Haynes, Mark K et al. (2018) High-Throughput Screening Approach for Identifying Compounds That Inhibit Nonhomologous End Joining. SLAS Discov 23:624-633
Orlow, Irene; Shi, Yang; Kanetsky, Peter A et al. (2018) The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. Pigment Cell Melanoma Res 31:287-296
Sharma, Geetanjali; Mauvais-Jarvis, Franck; Prossnitz, Eric R (2018) Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. J Steroid Biochem Mol Biol 176:31-37
Perez, Dominique R; Edwards, Bruce S; Sklar, Larry A et al. (2018) High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen. SLAS Discov 23:751-760

Showing the most recent 10 out of 344 publications